US EditionCohance Lifesciences appoints Yann D’Herve as CEO of CDMO business - Express Pharma
Summary by Express Pharma
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Cohance Lifesciences appoints Yann D’Herve as CEO of CDMO business - Express Pharma
Cohance Lifesciences, an integrated Contract Development and Manufacturing Organisation (CDMO), has announced the appointment of Yann D’Herve as Chief Executive Officer of its CDMO business, effective 1 August 2025. D’Herve brings senior-level leadership experience across pharmaceuticals, healthcare, and specialty chemicals. Prior to joining Cohance, he served as Senior Vice President and General Manager of Evonik’s Healthcare division. In that …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
